Blood test screens for dozens of cancers at once
A blood test that screens for more than fifty types of cancer simultaneously has cleared a key FDA advisory committee. Ten experts voted unanimously that its benefits outweigh its risks.
The Galleri test, developed by biotech firm Grail, analyzes fragments of genetic material that cancer cells shed into the bloodstream (circulating tumor DNA). A single blood draw can screen for more than fifty cancer types. That makes it fundamentally different from existing tests, which each target one specific cancer.
An FDA advisory panel evaluated the test on three criteria. It voted 10 to 0 that the test is safe. On effectiveness, the vote was split: six members for, four against. On the balance of benefits and risks, seven voted in favor, two against, with one abstention. The FDA is not legally obligated to follow advisory panel recommendations, but it typically does.
Early detection as a longevity question
Cancer is one of the leading causes of premature death and reduced quality of life. Many cancers are highly treatable when caught early, but at that point there are often no symptoms yet. A population-wide blood test could close that gap.
The review of the Galleri test confirms the method works, but the panel was divided on whether the effectiveness data are sufficiently robust. Critics point to the risk of false positives: people incorrectly told they may have cancer could face unnecessary follow-up procedures and anxiety. That is a genuine concern in large-scale screening of healthy populations.
What happens next
If the FDA approves the test, Galleri would become the first commercially available multi-cancer blood test with full regulatory clearance in the US. Whether broader rollout becomes realistic in other countries depends on equivalent approval processes by other regulatory bodies.
Search terms to explore further: circulating tumor DNA blood test | multi-cancer early detection | liquid biopsy cancer screening